JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

Kodu・Aktsiate loetelu・Vaxart Inc

Vaxart Inc

Suletud

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Põhinäitajad
By Trading Economics
Sissetulek	6.8M -8.1M
Müük	33M 72M
Aktsiakasum	-0.04
Kasumimarginaal	-11.242
Töötajad	105
EBITDA	6.7M -5.4M

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	19. märts 2026

Turustatistika
By TradingEconomics
Turukapital	55M 146M
Eelmine avamishind	0
Eelmine sulgemishind	0

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.4007 / 0.4252 Toetus ja vastupanu

Vaxart Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

9. veebr 2026, 17:25 UTC

Omandamised, ülevõtmised, äriostud

Eli Lilly to Buy Biotech Orna Therapeutics for Up to $2.4 Billion -- Update

9. veebr 2026, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for Domestic Policy Measures -- Market Talk

9. veebr 2026, 23:43 UTC

Market Talk

Gold Falls on Possible Technical Correction -- Market Talk

9. veebr 2026, 23:14 UTC

Market Talk

WiseTech's Bull Reckons AI-Driven Selloff Is Overdone -- Market Talk

9. veebr 2026, 22:29 UTC

Market Talk

Australian Coking Coal Price Seen Falling Once Supply Disruptions Ease -- Market Talk

9. veebr 2026, 22:19 UTC

Market Talk

Pro Medicus's Business Case Made More Compelling by AI Adoption -- Market Talk

9. veebr 2026, 22:08 UTC

Market Talk

Minerals 260 Bull Bets on Production Scale, Takeover Appeal -- Market Talk

9. veebr 2026, 22:01 UTC

Tulu

Friedman Industries Sees 4Q Sales Volume to Generally Consistent With 3Q, With Sequential Improvement in Sales Margins

9. veebr 2026, 21:59 UTC

Tulu

Friedman Industries: Hedging Activities Continued to Perform as Anticipated by Mitigating Impact of Commodity Price Volatility

9. veebr 2026, 21:59 UTC

Tulu

Friedman Industries: Average Selling Prices Began to Improve as Quarter Progressed

9. veebr 2026, 21:58 UTC

Tulu

Friedman Industries 3Q Sales $168M >FRD

9. veebr 2026, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Financial Services Roundup: Market Talk

9. veebr 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. veebr 2026, 21:48 UTC

Tulu

Friedman Industries 3Q EPS 43c >FRD

9. veebr 2026, 21:17 UTC

Tulu

Kyndryl Stock Drops 55%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

9. veebr 2026, 21:13 UTC

Market Talk

U.S. Ethanol Crush Margins Near Break-Even -- Market Talk

9. veebr 2026, 21:04 UTC

Tulu

Retail Sales Data Should Confirm a Robust Holiday Season -- Barrons.com

9. veebr 2026, 20:30 UTC

Market Talk

Oil Futures Gain As U.S.-Iran Risk Premium Holds -- Market Talk

9. veebr 2026, 20:02 UTC

Market Talk

U.S. Natural Gas Falls on Warmer Weather Outlook -- Market Talk

9. veebr 2026, 19:42 UTC

Market Talk

Japan's Yield Curve Expected to Flatten -- Market Talk

9. veebr 2026, 19:31 UTC

Market Talk

Nike Seen Regaining Relevance With Consumers -- Market Talk

9. veebr 2026, 19:27 UTC

Market Talk

Gold Climbs Back Over $5,000/oz -- Market Talk

9. veebr 2026, 19:05 UTC

Market Talk

Nike Returns to List of Hottest Brands -- Market Talk

9. veebr 2026, 18:19 UTC

Market Talk

Lower Dollar Doesn't Translate to Boost in Grains -- Market Talk

9. veebr 2026, 17:41 UTC

Tulu

Omandamised, ülevõtmised, äriostud

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, AppLovin, Monday.com, Valaris, and More -- Barrons.com

9. veebr 2026, 17:31 UTC

Tulu

Omandamised, ülevõtmised, äriostud

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, Monday.com, Valaris, Cleveland-Cliffs, and More -- Barrons.com

9. veebr 2026, 17:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Financial Services Roundup: Market Talk

9. veebr 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. veebr 2026, 17:17 UTC

Market Talk

Century Aluminum Announces Next Steps of Okla. Project -- Market Talk

9. veebr 2026, 17:16 UTC

Tulu

Kyndryl Stock Drops 56%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Vaxart Inc Prognoos

Hinnangu Konsensus

By TipRanks

0 ratings

Osta

Hoia

Müü

Põhineb 0 analüütiku instrumendi Vaxart Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.4007 / 0.4252Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.